Sales down, but profit up again in Philips' Q3
This article was originally published in Clinica
Executive Summary
Philips Healthcare once again managed to expand its bottom line during a tough third quarter: sales fell 8% to €2.26bn ($3.09bn), but earnings before interest, taxes and amortization grew to €329m, compared with €305m during the same period last year. Foreign exchange rates had a negative impact on revenues, with healthcare sales flat on a constant currency basis. By division, Customer Services saw “mid-single-digit growth,” while Home Healthcare Solutions and Patient Care & Clinical Information both reported “low-single-digit growth,” and Imaging Systems posted a “mid-single-digit decline.” The firm’s cost-cutting efforts are continuing to pay off – Philips says it has reduced its healthcare headcount by 659 versus Q3 2012, mainly due to cuts in North America and Europe. Its Accelerate! program saved the group €183m in Q3, taking the total gross savings to date to €856m. The company’s latest performance echoes similar results in Q2 and Q1 (www.clinica.co.uk, 22 April 2013).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.